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technical importance is the RT field arrangement, where the 
trend is using more complex dose planning. However, in the 
complex IMRT plans often more low-dose is distributed into 
large volumes of organs at risk, and that may be a bad 
decision increasing the risk of late morbidity. More patients 
are receiving adjuvant systemic therapies today compared to 
previously, and these therapies may partly reduce the gain 
from RT because they themselves reduce the risk of LRR, and 
partly because they may increase the risk of late morbidity 
after RT. This may be the case for RT-related morbidities like 
the risk of ischemic heart disease, damage to the brachial 
plexus, risk of lymph oedema and impaired shoulder 
movement. The risk of RT-induced second cancer is also 
important since it may be as high as 1:200, thus of the same 
magnitude as the risk of RT-induced heart disease (Grantzau 
et al, R&O, 2013). 
In conclusion, new studies are now supporting earlier studies 
showing gain from regional RT also in pN1 patients, but there 
is still a risk of RT related morbidity which must be dealt 
with. Therefore we need focus on identifying those patients 
who benefit from the RT, and we need a solid basis for 
selecting those patients who can be spared from RT. Studies 
on gene risk profiles to help us identify patients with benefit 
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SBRT for lung tumors has become an effective and safe 
routine procedure in many centers. However, due to 
historical developments, there is still a large diversity in 
doses and fractionation regimens. 
In this teaching lecture, an overview of current dose and 
fractionation regimens for different clinical scenarios of lung 
SBRT will be given and discussed in the light of outcome and 
normal tissue toxicity.  
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Classically detector response in small fields was considered 
to be influenced by two key factors: volume-averaging and 
differences between the photon spectra of small and large 
fields. Therefore it was thought that an ideal detector should 
be small in comparison to the dimensions of the fields it was 
used to measure, and have an atomic composition similar to 
water so that detector response would vary with fluence 
spectrum in the same way as dose-to-water. Consequently 
small air ion chambers and diamond detectors were 
identified as promising small field dosimeters.  
For some time it has also been known that differences 
between the fluence spectra of small and intermediate (4×4 
cm2) fields are insufficiently large to generate appreciable 
variations in the response of silicon-based detectors relative 
to water, and thus that diode detectors may be another good 
option for small field dosimetry, provided their calibration is 
‘daisy-chained’ from the usual 10×10 cm2 reference fields via 
a 3×3 or 4×4 cm2 intermediate. 
More recently it has been understood that as lateral 
electronic equilibrium (LEE) begins to break down (in fields 
narrower than 1.5 cm for a 6 MV beam) so response begins to 
be substantially influenced by the density of the detector 
sensitive volume (Figure 1), a non-classical factor which has 
no impact on response in wider fields. This finding has two 
implications for small field dosimetry: (i) it allows a small 
field to be defined physically as one in which LEE does not 
hold, rather than operationally with respect to detector size; 
(ii) it raises questions about the optimality of some air ion 
chambers, diodes and diamond detectors for small field 
dosimetry, as the sensitive volumes of these detectors have 
densities .001, 2.3 and 3.5 that of water, and it suggests that 
liquid ion chambers and plastic scintillators with roughly unit 
densities may make better detectors. 
Very recently, however, it has been appreciated that 
response is influenced not just by the density of a detector 
sensitive volume, but also by the densities of detector 
components lying close to it; and therefore that the response 
of diodes, diamond detectors, and potentially air ion 
chambers in small fields can be improved by using density 
compensation. In the case of a solid-state detector this 
involves building a small air cavity into the detector, 
upstream of the sensitive volume. In this lecture more details 
are provided of detector response in small fields and the 
factors underlying it. Density compensation techniques are 
also outlined, and results from an evaluation of a prototype 
density-compensated PTW diode-Air detector are presented. 
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Figure 1. Response of four detectors in small fields, defined 
via the Alfonso k correction factor as the dose-to-water to 
dose-to-detector ratio in a small field divided by the same 
ratio in a reference (3×3 cm2) field, plotted for: (a) the 
whole detector vs a point of water; (b) whole detector vs a 
water voxel of the same size as the detector sensitive 
volume; (c) sensitive volume alone versus water voxel of the 
same size; (d) sensitive volume with density adjusted to that 
of water vs water voxel of the same size.      
Teaching Lecture: Radiobiology on particle therapy 
SP-0351   
Radiobiology in particle therapy  
M. Durante1 
1GSI Helmholtz Centre for Heavy Ion Research, Biophysics 
Department, Darmstadt, Germany  
Densely ionizing radiation deposits the energy by 
electromagnetic or nuclear interactions along the tracks. This 
non-uniform energy deposition patterns generates a high 
number of clustered DNA lesions, which are difficult to 
repair. Therefore, protons, alpha particles, and heavy ions 
are generally more effective than X-rays in inducing 
biological damage.  For many years, particle therapy 
radiobiology concentrated on measurements of the relative 
biological effectiveness (RBE) of the energetic particles for 
tumour cell killing, generally using in vitro cell cultures 
exposed in monolayers at high-energy particle accelerators, 
such as the BEVALAC (Berkeley, USA), HIMAC (Chiba, Japan), 
and GSI (Darmstadt, Germany). The RBE-LET relationship is 
well known, and the large variability reflects the variance of 
the RBE, which is dependent upon many physical, chemical, 
and biological parameters.  More recently, it has been shown 
that densely ionizing radiation elicits signaling pathways 
quite distinct from those involved in the cell and tissue 
response to photons. The response of the microenvironment 
to charged particles is therefore under scrutiny, and both the 
damage in the target and non-target tissues are relevant. 
Hypofractionation, combined treatment modalities, and 
dose/LET painting are now under study in several accelerator 
facilities for clinical translation. Particle radiobiology is 
therefore now entering into a new phase, where beyond RBE 
the tissue response is considered. These results may open 
new applications in cancer therapy with charged particles 
(hadrontherapy). 
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Proton therapy makes it possible to treat cancer more 
effectively and with fewer side effects than is often the case 
with conventional radiotherapy. With proton therapy, the risk 
of damage to healthy tissues can be brought to a minimum 
for a number of clinical indications. These attractive 
properties have led to a rapid expansion of the proton 
treatment capacity worldwide. As a matter of fact, the 
number of proton facilities is increasing exponentially and 
proton therapy will soon be widely available and not merely 
an exotic option only for a few highly specialised centres. For 
this reason, there is a need for a broader understanding of 
proton therapy, its potentials, but also its limitations and 
potential pitfalls. 
Proton therapy is often claimed to be “more precise” than 
conventional radiotherapy. This is because the dose 
distribution can be modulated also in the depth direction, 
contrary to IMRT where the depth dose distribution is more or 
less invariant with the modulation. This possibility does not, 
however, necessarily significantly improve the conformity of 
the high dose volume since e.g. the penumbra in many cases 
are worse than what can be achieved with photons. The rapid 
dose fall-off at the end of the proton track can be used to 
obtain sharp dose gradients and hence a highly tailored dose 
distribution, but unfortunately, due to uncertainties in the 
estimated range of the proton beam, this property is not 
possible to explore to its full potential. The fundamental and 
remaining advantage with proton therapy is hence the 
significant reduction to non-target tissues and a reduction in 
side effects. 
For most of the large groups of cancer patients, the highest 
level of evidence for the superiority of proton treatment over 
conventional radiotherapy is still lacking. There is an ongoing 
discussion about the potential ethical dilemma of 
randomising patients between standard radiotherapy and 
proton therapy which is “known” to be better. However, a 
large number of clinical trials are designed and the 
knowledge regarding the best use of proton therapy will 
increase over the coming years. What can be assumed with a 
reasonable high degree of evidence is that proton therapy, 
correctly applied, will decrease late toxicity and since less 
dose is deposited in non-target tissues, the risk of developing 
a new, radiation-induced cancer later in life is significantly 
reduced. This is of particular importance in paediatric 
patients. 
